Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Clinical Comparison of Everolimus-Eluting SYNERGY and Biolimus-Eluting BioMatrix NeoFlex Coronary Stents in Non-Selected Patients With Ischemic Heart Disease

Next Previous
Trial Profile

Randomized Clinical Comparison of Everolimus-Eluting SYNERGY and Biolimus-Eluting BioMatrix NeoFlex Coronary Stents in Non-Selected Patients With Ischemic Heart Disease

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SORT-OUT VIII

Most Recent Events

  • 06 Jun 2019 Results of a pre-specified sub-study assessing 12-month clinical outcomes in patients with and without diabetes treated with EES or BES, published in the American Journal of Cardiology
  • 25 Sep 2018 Results of the secondary endpoints at 1-year follow-up are not available yet, but will be presented at TCT as per results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
  • 25 Sep 2018 Results of SORT OUT VIII substudy reporting the outcomes of stents in patients with and without diabetes presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top